This Cooperative Agreement award of $297,917 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports a Phase 1 clinical safety trial of the TRL1068 antibody therapeutic developed by Trellis Bioscience, Inc. The antibody is designed to disrupt bacterial biofilms and enhance the efficacy of conventional antibiotics. Prior SBIR and CARB-X funded research demonstrated the antibody's efficacy in rodent models and a positive safety profile in a prosthetic joint infection study. This Cooperative Agreement will fund a study to evaluate the safety of administering the TRL1068 antibody via nebulized inhalation in healthy adult volunteers, with the goal of developing it as an inhaled therapeutic for bronchial infections. The award period runs from July 2024 through December 2024.
Generated 3/25/25, 2:43 AM